

Malignant Melanoma: Update Bulletin [Jan 2016]

<https://marketpublishers.com/r/M6EC9DB3295EN.html>

Date: December 2015

Pages: 0

Price: US\$ 995.00 (Single User License)

ID: M6EC9DB3295EN

Abstracts

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo's (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy's (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA's approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma's binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen's newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy's superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy's uptake in stage III melanoma?

How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo's (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy's (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA's approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma's binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen's newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy's superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy's uptake in stage III melanoma?

How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

I would like to order

Product name: Malignant Melanoma: Update Bulletin [Jan 2016]

Product link: <https://marketpublishers.com/r/M6EC9DB3295EN.html>

Price: US\$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6EC9DB3295EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970